Government Research Grant Approval for Quantum Immunologics
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
The total amount awarded is $646,000.00, which corresponds with the three development projects:
1. Dendritic cell therapy for treatment of breast cancer -- QI is developing an OFA/iLRP loaded autologous dendritic cell technology which represents a new therapeutic approach to the treatment of breast cancer utilizing the patient's own immune system.
2. Development of OFA/iLRP peptides for the treatment of cancer -- The development of OFA/iLRP peptides main goal is to provide a process improvement for our dendritic cell therapy. This technology represents a new therapeutic target to treat cancer utilizing the patient's own immune system.
3. Development of monoclonal antibodies against OFA/iLRP for the treatment and diagnosis of cancer -- This research is focused on utilizing monoclonal antibodies against specific peptide regions of the oncofetal antigen (OFA).
According to Chairman and CEO Chuck Broes, "The award of these grants represents an outstanding mark of achievement for QI's scientific endeavors. In addition, QI's shareholder base should feel very confident about the further strengthening of its financial position. This award provides the Company with significant funds that not only bolsters its operating capital but is also non-dilutive to our existing shareholders."
1. Dendritic cell therapy for treatment of breast cancer -- QI is developing an OFA/iLRP loaded autologous dendritic cell technology which represents a new therapeutic approach to the treatment of breast cancer utilizing the patient's own immune system.
2. Development of OFA/iLRP peptides for the treatment of cancer -- The development of OFA/iLRP peptides main goal is to provide a process improvement for our dendritic cell therapy. This technology represents a new therapeutic target to treat cancer utilizing the patient's own immune system.
3. Development of monoclonal antibodies against OFA/iLRP for the treatment and diagnosis of cancer -- This research is focused on utilizing monoclonal antibodies against specific peptide regions of the oncofetal antigen (OFA).
According to Chairman and CEO Chuck Broes, "The award of these grants represents an outstanding mark of achievement for QI's scientific endeavors. In addition, QI's shareholder base should feel very confident about the further strengthening of its financial position. This award provides the Company with significant funds that not only bolsters its operating capital but is also non-dilutive to our existing shareholders."
